Pregnancy Clinical Trial
— C-it-DU-itOfficial title:
A Pragmatic Open-label, Community-based, Cluster Randomised Controlled Superiority Trial to Evaluate the Efficacy and Cost-effectiveness of Digital Data Linkage and Scheduling ('C-it') With or Without Community Data Use ('DU-it') to Increase Antenatal Clinic Uptake in Western Kenya.
The investigators propose to increase ANC uptake through a health systems strengthening approach that links digital data platforms and trains community Work Improvement Teams (WITs) to use these data to identify problems and come up with local solutions. Our short name C-it DU-it (pronounced "see-it; do-it") is an acronym intended to convey 'seeing' linked data (C-it) and 'doing' or acting on the data (DU-it). The trial design is a 2-arm, cluster-randomised controlled superiority trial in Homa Bay County to determine the efficacy of 'C-it DU-it' intervention (data use arm) to increase ANC contacts when compared to the 'C-it' enhanced standard of care (control arm).
Status | Not yet recruiting |
Enrollment | 1440 |
Est. completion date | September 30, 2026 |
Est. primary completion date | September 30, 2025 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | N/A and older |
Eligibility | Inclusion Criteria: - Pregnant women of all ages willing to participate - Written informed consent - A resident of the study area (catchment area) for the duration of the pregnancy - Delivered and still within the 6-week post-partum period. Exclusion Criteria: - Currently enrolled in another interventional study targeting pregnant women - Outside the 6-week post-partum period. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Liverpool School of Tropical Medicine | Kenya Medical Research Institute, LVCT Health |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Improving uptake of four ANC tests. | The proportion of women receiving testing and management of all four common conditions in pregnancy (HIV, syphilis, malaria, anaemia). | 14 months | |
Other | Improving uptake of HIV prevention services. | The proportion of HIV-negative women receiving testing and management for HIV in the 3rd trimester or at delivery.
The proportion of HIV-exposed infants with negative HIV PCR DNA tests at 6-8 weeks. |
14 months | |
Primary | Increasing antenatal clinic uptake | The proportion of women having at least eight ANC contacts during the antenatal period, defined as either a scheduled ANC visit in the facility or a scheduled ANC contact with a CHV in the community assessed at birth (or within the first 6-8 weeks for home births) using the ANC cards. | 14 months | |
Primary | Estimate socioeconomic impact and access to social protection | Defined as the proportion of women using financial coping strategies and their frequency and distribution | 14 months | |
Primary | Estimate the costs to pregnant women and their households | Absolute costs to the pregnant woman and their household and the costs as a proportion of the pregnant woman and their household's monthly income or expenditure/consumption will be calculated for the following variables:
Out-of-pocket medical costs Out-of-pocket non-medical costs Lost income, time, and productivity |
14 months | |
Secondary | The proportion of women having at least four scheduled ANC visits in the facility | assessed at birth (or within the first 6-8 weeks after birth for home births) using the ANC cards. | 14 months | |
Secondary | The proportion of women having at least eight scheduled ANC visits in the facility | assessed at birth (or within the first 6-8 weeks after birth for home births) using the ANC cards. | 14 months | |
Secondary | The frequency (count) of scheduled ANC visits | assessed at birth (or within the first 6-8 weeks after birth for home births) using the ANC cards. | 14 months | |
Secondary | The frequency (count) of of ANC visits in the community | assessed at birth (or within the first 6-8 weeks after birth for home births) using the ANC cards. | 14 months | |
Secondary | Early antenatal clinic attendance | The proportion of women with a first ANC contact before 16 weeks gestation. | 14 months | |
Secondary | Quality of antenatal care | The proportion of women with at least three courses of IPTp
The proportion of women who received iron and folate for 90 days. The proportion of women receiving testing and management for HIV. The proportion of women receiving testing and management for malaria. The proportion of women receiving testing and management for syphilis. The proportion of women receiving testing and management for anaemia. |
14 months | |
Secondary | Uptake of skilled birth attendance. | The proportion of women who had a skilled birth attendance. | 14 months | |
Secondary | Reducing the risk of adverse pregnancy outcomes. | The proportion of women with adverse pregnancy outcomes- defined as a composite of foetal loss (stillbirth or spontaneous miscarriage), low birth weight or neonatal mortality) | 14 months | |
Secondary | prevalence of catastrophic health expenditure (CHE) of accessing ANC care with "C-it" enhanced standard of care | CHE prevalence at two World Health Organization-defined thresholds: out-of-pocket medical costs of more than 10% of a patient household's total monthly expenditure/consumption (10%-threshold); and out-of-pocket medical costs of more than 40% of a patient household's monthly capacity to pay (non-food/housing/utilities expenditure/consumption)
• A sensitivity analysis of the proportion of women's households incurring CHE due to pregnancy and ANC visits using varying additional recognised calculations and thresholds including, as per WHO Tuberculosis Patient Cost Survey methodology, the addition of non-medical out-of-pocket costs and lost income in the numerator |
14 months | |
Secondary | Cost-effectiveness of "C-it" and "C-it DU-it" intervention | Incremental cost-effectiveness ratios (ICERs) compared across trial arms | 14 months | |
Secondary | Assess equity of access to ANC and "C-it" and "C-it DU-it" intervention. | Equity of access to ANC and the interventions will be evaluated by exploratory distributional (or "extended") cost-effectiveness analysis of the intervention across the following sub-groups: poverty quintiles, age groups including adolescents vs adults, study sites, HIV status, and by eligibility for health insurance including NHIF and Linda Mama. | 14 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03442582 -
Afluria Pregnancy Registry
|
||
Terminated |
NCT02161861 -
Improvement of IVF Fertilization Rates, by the Cyclic Tripeptide FEE - Prospective Randomized Study
|
N/A | |
Not yet recruiting |
NCT05934318 -
L-ArGinine to pRevent advErse prEgnancy Outcomes (AGREE)
|
N/A | |
Enrolling by invitation |
NCT05415371 -
Persistent Poverty Counties Pregnant Women With Medicaid
|
N/A | |
Completed |
NCT04548102 -
Effects of Fetal Movement Counting on Maternal and Fetal Outcome Among High Risk Pregnant Woman
|
N/A | |
Completed |
NCT03218956 -
Protein Requirement During Lactation
|
N/A | |
Completed |
NCT02191605 -
Computer-delivered Screening & Brief Intervention for Marijuana Use in Pregnancy
|
N/A | |
Completed |
NCT02223637 -
Meningococcal Quadrivalent CRM-197 Conjugate Vaccine Pregnancy Registry
|
||
Recruiting |
NCT06049953 -
Maternal And Infant Antipsychotic Study
|
||
Completed |
NCT02577536 -
PregSource: Crowdsourcing to Understand Pregnancy
|
||
Not yet recruiting |
NCT06336434 -
CREATE - Cabotegravir & Rilpivirine Antiretroviral Therapy in Pregnancy
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT05412238 -
Formulation and Evaluation of the Efficacy of Macro- and Micronutrient Sachets on Pregnant Mothers and Children Aged 6-60 Months
|
N/A | |
Not yet recruiting |
NCT04786587 -
Alcohol Self-reporting During Pregnancy. AUTOQUEST Study.
|
||
Not yet recruiting |
NCT05028387 -
Telemedicine Medical Abortion Service Using the "No-test" Protocol in Ukraine and Uzbekistan.
|
||
Completed |
NCT02683005 -
Study of Hepatitis C Treatment During Pregnancy
|
Phase 1 | |
Completed |
NCT02783170 -
Safety and Immunogenicity of Simultaneous Tdap and IIV in Pregnant Women
|
Phase 4 | |
Recruiting |
NCT02507180 -
Safely Ruling Out Deep Vein Thrombosis in Pregnancy With the LEFt Clinical Decision Rule and D-Dimer
|
||
Recruiting |
NCT02619188 -
Nutritional Markers in Normal and Hyperemesis Pregnancies
|
N/A | |
Recruiting |
NCT02564250 -
Maternal Metabolism and Pregnancy Outcomes in Obese Pregnant Women
|
N/A | |
Completed |
NCT02528136 -
The Clinical Carbetocin Myocardium Trial
|
Phase 4 |